Latest news
CytoSorbents (NASDAQ: CTSO) posts Q2 2026 revenue of $9.6M and narrows loss - Stock TitanStock Titan · Fri, 07 Aug 2026 20:07:30 GMTCytoSorbents Q2 2026: Flat Revenue, Improved Cash Burn Ahead of DrugSorb-ATR FDA Decision - The Clinical Trial VanguardThe Clinical Trial Vanguard · Fri, 07 Aug 2026 06:44:00 GMTCTSO: Gross margin improved to 73% as cash burn fell, with regulatory and commercial progress ongoing - TradingViewTradingView · Thu, 06 Aug 2026 22:54:45 GMTCytoSorbents Q2 2026 earnings: Margins improve despite flat revenue - TradingKeyTradingKey · Thu, 06 Aug 2026 21:43:51 GMTCytoSorbents plans early-2027 FDA filing for blood-thinner device - Stock TitanStock Titan · Thu, 06 Aug 2026 20:25:00 GMTCTSO|Cytosorbents Corp|Price:0.358|Chg%:-0.003 - TradingKeyTradingKey · Fri, 31 Jul 2026 07:00:00 GMT